HC Wainwright Brokers Reduce Earnings Estimates for Foghorn Therapeutics Inc. (NASDAQ:FHTX)

Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) – Analysts at HC Wainwright reduced their Q2 2023 earnings per share (EPS) estimates for Foghorn Therapeutics in a research report issued to clients and investors on Tuesday, May 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.78) per share for […]

Related Keywords

United States ,America , ,Raymond James Associates ,Millennium Management ,Barclays Plc ,Russell Investments Group Ltd ,Foghorn Therapeutics Inc ,Nasdaq ,Man Group ,Foghorn Therapeutics ,Get Rating ,Foghorn Therapeutic ,Investments Group ,Therapeutics Inc ,Gene Traffic Control ,Foghorn Therapeutics Daily ,Nasdaq Fhtx ,Fhtx ,Medical ,Earnings Estimates ,Hc Wainwright ,